Preclinical evaluation of [111In]-DOTA-trastuzumab for clinical trials | Zendy

Amir Reza Jalilian | Zendy; Behrouz Alirezapour | Zendy; Saeed Rajabifar | Zendy; M. Mirzaii | Zendy; Sedigheh Moradkhani | Zendy; Mehraban Pouladi | Zendy; Gholamreza Aslani | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Preclinical evaluation of [¹¹¹In]-DOTA-trastuzumab for clinical trials

Author(s) -

Amir Reza Jalilian,

Behrouz Alirezapour,

Saeed Rajabifar,

M. Mirzaii,

Sedigheh Moradkhani,

Mehraban Pouladi,

Gholamreza Aslani

Publication year - 2014

Publication title -

journal of cancer research and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.475

H-Index - 39

eISSN - 0973-1482

pISSN - 1998-4138

DOI - 10.4103/0973-1482.131434

Subject(s) - dota , skbr3 , trastuzumab , internalization , radioimmunoassay , chemistry , context (archaeology) , in vivo , in vitro , conjugate , antibody , nuclear medicine , microbiology and biotechnology , medicine , chelation , cell , cancer , immunology , cancer cell , biochemistry , breast cancer , biology , mathematical analysis , human breast , mathematics , organic chemistry , paleontology

Herceptin and its fragments have been radiolabeled and used in the imaging of human epidermal growth factor receptor 2 (HER2)/neu-positive tumors and development of diagnostic kits is of great importance in radiopharmacy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research